Mark Jiang

Foodie. Hematologist/oncologist at @LAGeneralMed. Former @BCMHemeOnc chief fellow and @ucsdim chief resident. Proud Cal Bear (@UCBerkeley) for life.

[Mark Jiang @markjyjiang]

Guess what happens when you give me a captive audience 😂

[Mark Jiang @markjyjiang]

In a cohort of pts with classical Hodgkin lymphoma enriched in advanced-stage, higher-risk, and HIV-associated disease and treated at @harrishealth, uninsurance was not associated with inferior outcomes. https://t.co/rpVfbuU433 @AngLi_MD @ChrisRFlowersMD @BCMHemeOnc

[Ang Li, MD, MS @AngLi_MD]

Tired of spending all day chart-reviewing to find acute venous #thrombosis (PE/DVT)?
Try our validated VTE-BERT, a fine-tuned #NLP #AI model that extracts #VTE outcomes from full clinical notes.
🔗 https://t.co/xcOocTwXrl
📄 https://t.co/zjnh6L4PVp
@JTHjournal @BCMDeptMedicine

[Mark Jiang @markjyjiang]

In our systematic review, we found persistent disparities in enrollment rates into lymphoma trials related to age, sex, gender, race, ethnicity, geography, and SES. https://t.co/c9ZzVfKjfR @AngLi_MD @ChrisRFlowersMD @BCMHemeOnc

[Diana Franco Betancourt @FrancoBetaDiana]

So proud of these brilliant friends now officially Hematologists and Oncologists! 👏I’m endlessly grateful fellowship brought you into my life.
Your next chapter will be lucky to have you ❤️ @Ibrahematology #Mark

[Marc Carrier @MarcCarrier1]

Dr. @AngLi_MD reported external validation of the EHR-CAT score (adaptions of the Khorana risk score) in 187 health care system (over 400,000 patients).

Let’s implement this in EPIC to stratify patients according to their underlying risk of VTE!
#ASH24

[Martha Mims @marthamims]

Mark Jiang too! Go BCM fellows!!

[Mark Jiang @markjyjiang]

ctDNA is an underexplored tool for the prognostication of cancer-associated VTE. The # of pathogenic ctDNA mutations is independently predictive of VTE risk. https://t.co/vQs9bw0D1g @JTHjournal @AngLi_MD @BCMHemeOnc

[Martha Mims @marthamims]

BCM fellows gather at ASH- so proud of our showing !!!

[Martha Mims @marthamims]

Looks like much too much fun at ASH- BCM fellows and a Grad!!

[Martha Mims @marthamims]

Wohoo Mark great poster! Congratulations fantastic work

[Mark Jiang @markjyjiang]

That moment when you got a lot more malignant heme in you than you thought and end up getting a cake reminiscent of leukemia blasts... Happy birthday to our phenomenal PD, Dr. Miller-Chism! @BCMHemeOnc

[Mark Jiang @markjyjiang]

Problem representations don't go away in fellowship! Practicing clinical reasoning with the med studs. #MedEd @BCMHemeOnc

[Mark Jiang @markjyjiang]

Hot off the press! Survival of large B-cell lymphoma pts treated at @harrishealth, a safety-net health system with robust financial assistance, was comparable to SEER estimates. R-IPI remains prognostic: https://t.co/nUcjzMAFeT. @AngLi_MD @ChrisRFlowersMD @BCMHemeOnc

[BCM Hematology-Oncology Fellowship @BCMHemeOnc]

It's true that we just said goodbye to our graduating fellows, but we also welcomed a new wonderful class of 11 fellows! Excited to see how these bright minds make cancer history. Say hi to the Class of 2027! @bcmhouston

[Mark Jiang @markjyjiang]

@hsafaMD @marthamims @BCMHemeOnc We tease the ones we love most. Proud of you, buddy!

[Hemali Batra-Sharma, MD @HBatraSharmaMD]

Heme/Onc fellows, I'm doing a MedEd project to help improve training on clinical trials & drug dev. Please fill out this anonymous 5-min survey to assess resources & gaps in fellowship training on this important topic! #MedTwitter #onctwitter https://t.co/LxnwvqD22h

[Mark Jiang @markjyjiang]

Here's an anticoagulation cheat sheet for those who find it helpful. For everything else, your friendly neighborhood hematologist is here to help! @BCMHemeOnc #BloodClots #MedTwitter

[BCM Hematology-Oncology Fellowship @BCMHemeOnc]

A big congratulations to our two new rising chief fellows @DrKaylaMiranda and @markjyjiang . We are very excited to have them to join the leadership of the fellowship program next academic year.

[Mark Jiang @markjyjiang]

Proud to be part of the team that brought you this study highlighting the natural history of #cancer-associated splanchnic vein #thrombosis, a poorly understood disease entity with a distinct clinical behavior from usual-site #VTE. @BCMHemeOnc

[JTH @JTHjournal]

Anticoagulation in #cancer-associated splanchnic vein #thrombosis (SpVT) requires judicious consideration for thrombotic & bleeding risk.

This study by Shang et al. delves deeper into the natural history & management of SpVT. @AngLi_MD
https://t.co/SMOYg7e4HC @ELShematology